Clinical Trial Update: Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating discontinuation of imatinib in chronic myeloid leukemia patients with deep molecular response; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: University of Campinas, Brazil | Conditions: Leukemia, Chronic Myeloid | Phase 2 | Status: COMPLETED